Developmental toxicities, sex disparities, and temporal kinetics of tyrosine kinase inhibitors in paediatric leukaemia: A real-world pharmacovigilance study

While tyrosine kinase inhibitors (TKIs) have significantly advanced paediatric leukaemia management, real-world safety signals and reported event timing in paediatric populations remain less defined compared to adults. We conducted a pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) to evaluate four TKIs (imatinib, dasatinib, nilotinib, and ponatinib). Standardised drug name mapping and deduplication protocols were applied. Disproportionality analyses (calculating reporting odds ratios [RORs] with 95% confidence intervals [CIs]) were performed to detect adverse drug event (ADE) signals. Weibull shape parameter analyses were used to evaluate the temporal distribution of reported time-to-onset among cases with available dates. Disproportionality analysis identified distinct ADE reporting signals in paediatric cases. Dasatinib showed a strong disproportionality signal for chylothorax (ROR, 315.78; 95% CI, 142.65-699.04; n = 7 events). Imatinib was associated with signals for physical development interference, including pubertal failure (ROR, 399.30; 95% CI, 103.24-1544.37; n = 7 events). Sex-stratified analyses did not demonstrate statistically significant differences in growth impairment between male and female patients. Time-to-onset distributions indicated that recorded onset dates were concentrated early in therapy, with 41.25% of imatinib-associated and 26.13% of dasatinib-associated ADE reports occurring within the first 30 days of treatment. Spontaneous reporting data reveal specific disproportionality signals and early reporting patterns for TKIs in paediatric patients. Although these findings cannot infer causality, true incidence, or underlying biological mechanisms due to FAERS database limitations, they generate meaningful safety hypotheses that support proactive clinical surveillance upon TKI initiation.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-11-13
DOI
https://doi.org/10.1186/s12885-026-17303-5
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Developmental toxicities, sex disparities, and temporal kinetics of tyrosine kinase inhibitors in paediatric leukaemia: A real-world pharmacovigilance study

Fangyu Song, Mo Sun, Tong Chen, Jinhao He et al.
1 links
BMC Cancer
Pharmacovigilance and Adverse Drug Reactions
article

Developmental toxicities, sex disparities, and temporal kinetics of tyrosine kinase inhibitors in paediatric leukaemia: A real-world pharmacovigilance study

Fangyu Song, Mo Sun, Tong Chen, Jinhao He, Jiaqi Sun, Jiali Xue, Lanlan Yan, Zijun Yan, Chenning Zhang
article en

Abstract

While tyrosine kinase inhibitors (TKIs) have significantly advanced paediatric leukaemia management, real-world safety signals and reported event timing in paediatric populations remain less defined compared to adults. We conducted a pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) to evaluate four TKIs (imatinib, dasatinib, nilotinib, and ponatinib). Standardised drug name mapping and deduplication protocols were applied. Disproportionality analyses (calculating reporting odds ratios [RORs] with 95% confidence intervals [CIs]) were performed to detect adverse drug event (ADE) signals. Weibull shape parameter analyses were used to evaluate the temporal distribution of reported time-to-onset among cases with available dates. Disproportionality analysis identified distinct ADE reporting signals in paediatric cases. Dasatinib showed a strong disproportionality signal for chylothorax (ROR, 315.78; 95% CI, 142.65-699.04; n = 7 events). Imatinib was associated with signals for physical development interference, including pubertal failure (ROR, 399.30; 95% CI, 103.24-1544.37; n = 7 events). Sex-stratified analyses did not demonstrate statistically significant differences in growth impairment between male and female patients. Time-to-onset distributions indicated that recorded onset dates were concentrated early in therapy, with 41.25% of imatinib-associated and 26.13% of dasatinib-associated ADE reports occurring within the first 30 days of treatment. Spontaneous reporting data reveal specific disproportionality signals and early reporting patterns for TKIs in paediatric patients. Although these findings cannot infer causality, true incidence, or underlying biological mechanisms due to FAERS database limitations, they generate meaningful safety hypotheses that support proactive clinical surveillance upon TKI initiation.

BMC Cancer
Hubei University of Medicine (CN), Georgia Institute of Technology (US), Chengdu Medical College (CN), Kunming Medical University (CN), Taihe Hospital (CN), Panzhihua Central Hospital (CN)
Innovative Research Group Project of the National Natural Science Foundation of China, Natural Science Foundation of Sichuan Province
Good health and well-being
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon